ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 22 of 3618 for:    Recruiting, Not yet recruiting, Available Studies | "Lung Diseases"

Longitudinal Observational Study on the Course of Cystic Fibrosis Lung Disease in Patients Following Newborn Screening (TRACK-CF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02270476
Recruitment Status : Recruiting
First Posted : October 21, 2014
Last Update Posted : May 17, 2018
Sponsor:
Collaborator:
German Center for Lung Research
Information provided by (Responsible Party):
Mirjam Stahl, Heidelberg University

Brief Summary:
The purpose of this study is to further characterize early CF lung disease in newborns, infants and toddlers with cystic fibrosis (CF).

Condition or disease
Cystic Fibrosis Lung Disease

Detailed Description:

Cystic fibrosis (CF) is the most common lethal genetic multisystem disease in Germany. Although life expectancy increased over the last decades, most of the CF patients die in young adulthood due to chronic CF lung disease with respiratory failure. CF lung disease is caused by a disturbed transport of salt and water by airway epithelia and dehydration of airway surfaces as a result of the underlying genetic defect in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gen. Up to now, no causal therapies for the majority of patients with CF are available. Little is known about onset and natural course as well as influencing factors of CF lung disease. Therefore, the first aim of this prospective, multicenter, uncontrolled, non-randomized, explorative longitudinal study is characterization of the onset and early course of CF lung disease. For this reason we will primarily include patients diagnosed by CF newborn screening (CF-NBS) or for any other reason in the first four months of life (early diagnosed, ED). In a second step we will compare data from these patients to those diagnosed clinically later in life (late diagnosed, LD). This will allow us to investigate the effect of early diagnosis and start of therapy. Starting at diagnosis, we will use data from annual routine check-ups (imaging like chest MRI, pulmonary function tests, microbiology from swabs and sputum, laboratory values, anthropometry) as well as data from a facultative, study-related bronchoscopy with lavage (microbiology, inflammation and immunology) for correlation with the course of CF lung disease (generation of hypotheses). Further study-related investigations are monthly telephone interviews on bronchopulmonary symptoms by a study nurse on the basis of a questionnaire and quarterly assessment of health-related quality of life on the basis of a validated questionnaire.

We expect to gain a deeper insight into onset and early course of CF lung disease from the results of this study. So far, there is no trial that investigated the different aspects of CF lung disease (function, morphology, infectiology, inflammation) complementary in a longitudinal setting. We assume that knowledge on the natural history of CF lung disease in the vulnerable phase of early childhood has a great impact on the future development of new therapies (from symptomatic to causal). This shall lead to a further improvement in life expectancy and quality of life of patients with CF.


Study Type : Observational
Estimated Enrollment : 200 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Longitudinal Observational Study on the Course of Cystic Fibrosis Lung Disease in Patients Following Newborn Screening
Study Start Date : December 2011
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : December 2022


Group/Cohort
Early diagnosed (ED)
Children diagnosed with CF in the first 4 months of life.
Late diagnosed (LD)
Children diagnosed with CF after the first 4 months of life.



Primary Outcome Measures :
  1. Proportion with morphological and/or perfusion changes due to CF lung disease after chest MRI score in both groups [ Time Frame: At age of 1, 2, 3, ...., 10 years of age ]
  2. Proportion of patients with impairments in pulmonary function tests (e.g. multiple breath washout (MBW)) in both groups [ Time Frame: At age of 1, 2, 3, ...., 10 years of age ]

Secondary Outcome Measures :
  1. Rate of protocol-defined pulmonary exacerbations in both groups (ED vs. LD) that are necessitating an antibiotic therapy orally, intravenously or per inhalation [ Time Frame: At age of 1, 2, 3, ...., 10 years of age ]
  2. Spontaneous development of infection or spectrum of pathogens, respectively, in throat and nose swabs as well as other airway secretions from routine diagnostics and if applicable bronchoalveolar lavage fluid (BALF) [ Time Frame: At age of 1, 2, 3, ...., 10 years of age ]
  3. From the patients in whom PsA or other CF pathogens could not be isolated at the beginning of their participation, comparison of the portion of patients with a positive culture during participation in both groups (ED and LD) [ Time Frame: At age of 1, 2, 3, ...., 10 years of age ]
  4. Time to first detection of a CF pathogen in both groups [ Time Frame: At age of 1, 2, 3, ...., 10 years of age ]
  5. Time to first pulmonary exacerbation in both groups [ Time Frame: At age of 1, 2, 3, ...., 10 years of age ]
  6. Portion of patients with increased biochemical inflammatory markers in both groups and magnitude of elevation [ Time Frame: At age of 1, 2, 3, ...., 10 years of age ]
  7. Frequency of symptoms from monthly telephone interviews in both groups [ Time Frame: At age of 1, 2, 3, ...., 10 years of age ]
  8. Health-related quality of life in both groups quarterly via Cystic Fibrosis Questionnaire (CFQ) [ Time Frame: At age of 1, 2, 3, ...., 10 years of age ]
  9. Development of body weight, body height, ideal weight-for-height (IWFH), Body-Mass-Index (BMI), respiratory rate and oxygen saturation at room air in both groups [ Time Frame: At age of 1, 2, 3, ...., 10 years of age ]
  10. Proportion with morphological changes due to CF lung disease after modified Chrispin-Norman Score for assessment of chest X-ray in both groups [ Time Frame: At age of 1, 2, 3, ...., 10 years of age ]
  11. Magnitude and severity of alterations typical for CF by assessment with chest MRI and X-ray score in both groups [ Time Frame: At age of 1, 2, 3, ...., 10 years of age ]
  12. Magnitude of impairment of pulmonary function test in both groups [ Time Frame: At age of 1, 2, 3, ...., 10 years of age ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with CF diagnosed in the first 4 months of life (corrected age of 4 months in preterms) not before January 1st, 2006 build up the early diagnosed (ED) group. Early identification can be achieved by newborn screening, clinical diagnosis (e.g. patients with meconium ileus), due to positive family history or prenatal diagnosis. Patients with CF diagnosed after the first 4 months of life and after January 1st, 2006, are included as a comparison group with clinically diagnosed patients (late diagnosed, LD). Both groups (ED and LD) are investigated after the same investigational plan with all investigations that are part of the annual check-up and additional, study-related monthly telephone interviews on bronchopulmonary symptoms, quarterly assessment of QoL and voluntarily yearly bronchoscopy with broncho-alveolar lavage.
Criteria

Inclusion Criteria:

  1. Newly diagnosed patients with Cystic Fibrosis (CF). Diagnosis of CF: at least one of the following three international accepted criteria is fulfilled: i) sweat chloride ≥ 60mEq/L and/or ii) 2 CF-causing mutations in the CFTR gene and/or iii) changes typical for CF in the transepithelial potential difference in nasal or rectal epithelium.
  2. Age and mode of diagnosis:

    • Early diagnosed (ED): Initial diagnosis following CF-NBS or for other reasons in the first 4 months of life (in preterms corrected age of 4 months) after January 1st, 2006. Other reasons could be prenatal diagnostics, meconium ileus or positive family history.
    • Late diagnosed (LD): Diagnosed after the fourth month of life due to clinical symptoms; initial diagnosis after January 1st, 2006.

Exclusion Criteria:

All patients are excluded who themselves or whose parents do not want to participate or that withdraw from the study; or those in whom the diagnosis of CF is unsure.

Further exclusion criteria are:

  1. Preterms <30th week of gestation
  2. Longer period of mechanical ventilation in first 3 months of life
  3. A significant medical disease or condition other than CF likely to interfere with the child's ability to complete the entire protocol
  4. Previous major surgery except for meconium ileus or atresia of the intestine
  5. Other major organ dysfunction, excluding pancreatic or hepatic dysfunction or another condition due to CF
  6. Physical findings that would compromise the safety of the subject or the quality of the study data as determined by investigator
  7. Chronic lung disease other than CF (e.g. bronchopulmonary dysplasia)
  8. History of adverse reaction to medication for sedation or known claustrophobia

Criteria, which lead to a displacement of the procedures in sedation until the child has recovered: - Clinically significant upper airway obstruction as determined by investigator (e.g.

severe laryngomalacia, markedly enlarged tonsils, significant snoring, diagnosed obstructive sleep apnoea)

- Severe gastroesophageal reflux, defined as persistent frequent emesis despite anti-reflux therapy


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02270476


Contacts
Contact: Marcus A Mall, MD +49 6221 56 4502 Marcus.Mall@med.uni-heidelberg.de
Contact: Mirjam Stahl, MD +49 6221 56 37049 Mirjam.Stahl@med.uni-heidelberg.de

Locations
Germany
University Children's Hospital Heidelberg, Cystic Fibrosis Centre Recruiting
Heidelberg, Baden-Württemberg, Germany, 69120
Contact: Marcus A Mall, MD    +49 6221 56 4502    Marcus.Mall@med.uni-heidelberg.de   
Contact: Mirjam Stahl, MD    +49 6221 56 37049    Mirjam.Stahl@med.uni-heidelberg.de   
Principal Investigator: Marcus A Mall, MD         
Principal Investigator: Olaf Sommerburg, MD         
Sub-Investigator: Mirjam Stahl, MD         
Sub-Investigator: Simon Y Gräber, MD         
Sub-Investigator: Susanne Hämmerling, MD         
University Hospital Gießen and Marburg GmbH Recruiting
Gießen, Hessen, Germany, 35392
Contact: Lutz Nährlich, MD    +49 (0) 641 985-57621    lutz.naehrlich@paediat.med.uni-giessen.de   
Principal Investigator: Lutz Nährlich, MD         
Medizinische Hochschule Hannover Recruiting
Hannover, Niedersachsen, Germany, 30625
Contact: Christian Dopfer, MD    +49 (0)1761 532 3325    dopfer.christian@mh-hannover.de   
Principal Investigator: Christian Dopfer, MD         
University Children's Hospital Schleswig-Holstein Recruiting
Lübeck, Schleswig-Holstein, Germany, 23538
Contact: Matthias V Kopp, MD    +49 (0) 451 5002550    matthias.kopp@uksh.de   
Principal Investigator: Matthias V Kopp, MD         
Sponsors and Collaborators
Heidelberg University
German Center for Lung Research
Investigators
Principal Investigator: Marcus A Mall, MD University Hospital Heidelberg

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Mirjam Stahl, PI and Leader of Junior Research Group, Heidelberg University
ClinicalTrials.gov Identifier: NCT02270476     History of Changes
Other Study ID Numbers: UKH-TRACK-1
First Posted: October 21, 2014    Key Record Dates
Last Update Posted: May 17, 2018
Last Verified: May 2018

Keywords provided by Mirjam Stahl, Heidelberg University:
Cystic Fibrosis
Infant
Toddler
Children
Newborn screening

Additional relevant MeSH terms:
Fibrosis
Cystic Fibrosis
Lung Diseases
Pulmonary Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases